Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Schrodinger, Inc. - Common Stock (NQ:SDGR)

25.75 +0.54 (+2.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Schrodinger, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Schrödinger to Announce Third Quarter 2022 Financial Results on November 3
From Schrödinger
Via Business Wire
Schrödinger Hosts Platform Day
From Schrödinger
Via Business Wire
Schrödinger to Host Platform Day on October 6, 2022
From Schrödinger, Inc.
Via Business Wire
7 Small-Cap Stock Picks to Beat the September Market Slump
With the macro environment not as dreary as the bears believe, investors should consider buying one or more of my small-cap stock picks. 
Via InvestorPlace
Schrödinger to Present at Citi’s 17th Annual BioPharma Conference
From Schrödinger, Inc.
Via Business Wire
Cathie Wood Loads Up $4.6M In Bill Gates-Backed Healthcare Tech Company
Cathie Wood-led Ark Investment Management on Thursday bought 162,276 shares of Schrodinger Inc (NASDAQ: SDGR) through the Ark Genomic Revolution ETF (BATS: ARKG), trading d 
Via Benzinga
Schrödinger Reports Inducement Grants To Newly Appointed Chief Financial Officer
From Schrödinger, Inc.
Via Business Wire
Schrödinger Appoints Geoffrey Porges as Chief Financial Officer
From Schrödinger, Inc.
Via Business Wire
Gain Therapeutics: Reasons For Optimism
In biotechnology, potential rules. And in Gain's case, the potential to not just treat but functionally cure at least some forms of Parkinson's Disease is strong enough to weather early-stage... 
Via Talk Markets
Schrödinger Reports Second Quarter 2022 Financial Results
From Schrödinger, Inc.
Via Business Wire
Schrödinger to Announce Second Quarter 2022 Financial Results on August 4
From Schrödinger
Via Business Wire
3 Biotech Stocks to Buy on the Dip
Biotech stocks have rebounded lately and are poised to keep surging, so it's a good time to buy biotech stocks on the dip. 
Via InvestorPlace
The 7 Best Stocks to Buy on a Dip in July
With the stock market pricing in a recession that likely won't arrive anytime soon, these are some of the best stocks to buy on a dip. 
Via InvestorPlace
Schrödinger's Initial-Stage Cancer Study Gains FDA Clearance
Schrödinger Inc. (NASDAQ: SDGR) announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for the drug candidate SGR-1505 in patients with... 
Via Benzinga
Schrödinger Announces FDA Clearance of Investigational New Drug Application for SGR-1505, a MALT1 Inhibitor
From Schrödinger, Inc.
Via Business Wire
Schrödinger Convenes Global Educators For Second Annual Educator’s Day
From Schrödinger, Inc.
Via Business Wire
Bill Gates Stocks: 7 Top Picks From the Gates Foundation Portfolio
These Bill Gates stocks are great picks to buy now. BRK-B, CNI, DE, ECL, MSFT, SDGR, and WM can make excellent long-term investments. 
Via InvestorPlace
Schrödinger to Present at Jefferies Healthcare Conference
From Schrödinger, Inc.
Via Business Wire
Schrödinger Announces Appointment of Arun Oberoi to Board of Directors
From Schrödinger, Inc.
Via Business Wire
Schrödinger to Present at Citi Biotech Virtual Co-Panel Day
From Schrödinger, Inc.
Via Business Wire
Recap: Schrodinger Q1 Earnings
Schrodinger (NASDAQ:SDGR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Schrodinger beat estimated earnings... 
Via Benzinga
Schrödinger Reports First Quarter 2022 Financial Results
From Schrödinger, Inc.
Via Business Wire
Schrödinger to Announce First Quarter 2022 Financial Results on May 4
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
AI Pharma Startup METiS Raises $150 Million. IPO In Sight?
Key takeaways: METiS Pharmaceuticals has completed five funding rounds since its establishment in January 2020, including the latest two worth $150 million The company was... 
Via Benzinga
Schrödinger New Preclinical Data Supports Development Of Its Wee1 Inhibitor In Cancer Indications
Schrödinger Inc (NASDAQ: SDGR)  
Via Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Schrödinger Reports New Preclinical Data Supporting Advancement of Its Wee1 Inhibitor Program at American Association of Cancer Research 2022 Annual Meeting
From Schrödinger, Inc.
Via Business Wire
3 Hypergrowth Tech Stocks to Buy for Huge Upside Potential
These hypergrowth stocks are bargains after retreating for much of the last year. They will all perform very well for long-term investors. 
Via InvestorPlace
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.